TY - JOUR
T1 - Targeting mTORs by omega-3 fatty acids
T2 - A possible novel therapeutic strategy for neurodegeneration?
AU - Shirooie, Samira
AU - Nabavi, Seyed Fazel
AU - Dehpour, Ahmad R.
AU - Belwal, Tarun
AU - Habtemariam, Solomon
AU - Argüelles, Sandro
AU - Sureda, Antoni
AU - Daglia, Maria
AU - Tomczyk, Michał
AU - Sobarzo-Sanchez, Eduardo
AU - Xu, Suowen
AU - Nabavi, Seyed Mohammad
N1 - Publisher Copyright:
© 2018 Elsevier Ltd
PY - 2018/9
Y1 - 2018/9
N2 - Neurodegenerative diseases (NDs) such as Parkinson's (PD), Alzheimer's (AD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS) cause significant world-wide morbidity and mortality. To date, there is no drug of cure for these, mostly age-related diseases, although approaches in delaying the pathology and/or giving patients some symptomatic relief have been adopted for the last few decades. Various studies in recent years have shown the beneficial effects of omega-3 poly unsaturated fatty acids (PUFAs) through diverse mechanisms including anti-inflammatory effects. This review now assesses the potential of this class of compounds in NDs therapy through specific action against the mammalian target of rapamycin (mTOR) signaling pathway. The role of mTOR in neurodegenerative diseases and targeted therapies by PUFAs are discussed.
AB - Neurodegenerative diseases (NDs) such as Parkinson's (PD), Alzheimer's (AD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS) cause significant world-wide morbidity and mortality. To date, there is no drug of cure for these, mostly age-related diseases, although approaches in delaying the pathology and/or giving patients some symptomatic relief have been adopted for the last few decades. Various studies in recent years have shown the beneficial effects of omega-3 poly unsaturated fatty acids (PUFAs) through diverse mechanisms including anti-inflammatory effects. This review now assesses the potential of this class of compounds in NDs therapy through specific action against the mammalian target of rapamycin (mTOR) signaling pathway. The role of mTOR in neurodegenerative diseases and targeted therapies by PUFAs are discussed.
KW - Docosahexaenoic acid
KW - Eicosapentaenoic acid
KW - mTOR
KW - Neurodegenerative diseases
KW - omega-3
UR - https://www.scopus.com/pages/publications/85050194568
U2 - 10.1016/j.phrs.2018.07.004
DO - 10.1016/j.phrs.2018.07.004
M3 - Review article
C2 - 29990625
AN - SCOPUS:85050194568
SN - 1043-6618
VL - 135
SP - 37
EP - 48
JO - Pharmacological Research
JF - Pharmacological Research
ER -